You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output.
Click here to find out more.
Mendeley readers
Attention Score in Context
| Title |
The role of immune checkpoint inhibition in the treatment of ovarian cancer
|
|---|---|
| Published in |
Gynecologic Oncology Research and Practice, November 2016
|
| DOI | 10.1186/s40661-016-0033-6 |
| Pubmed ID | |
| Authors |
Stéphanie L. Gaillard, Angeles A. Secord, Bradley Monk |
| Abstract |
The introduction of immune checkpoint inhibitors has revolutionized treatment of multiple cancers and has bolstered interest in this treatment approach. So far, emerging clinical data show limited clinical efficacy of these agents in ovarian cancer with objective response rates of 10-15% with some durable responses. In this review, we present emerging clinical data of completed trials of immune checkpoint inhibitors and review ongoing studies. In addition we examine the current knowledge of the tumor microenvironment of ovarian cancers with a focus on the significance of PD-L1 expression and tumor-infiltrating lymphocytes on predicting response to immune checkpoint blockade. We evaluate approaches to improve treatment outcomes through the use of predictive biomarkers and patient selection. Finally, we review management considerations including immune related adverse events and response criteria. |
Mendeley readers
The data shown below were compiled from readership statistics for 181 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| India | 1 | <1% |
| Unknown | 180 | 99% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Student > Ph. D. Student | 36 | 20% |
| Researcher | 33 | 18% |
| Student > Bachelor | 23 | 13% |
| Student > Master | 19 | 10% |
| Other | 12 | 7% |
| Other | 21 | 12% |
| Unknown | 37 | 20% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 49 | 27% |
| Biochemistry, Genetics and Molecular Biology | 40 | 22% |
| Agricultural and Biological Sciences | 19 | 10% |
| Immunology and Microbiology | 14 | 8% |
| Chemistry | 4 | 2% |
| Other | 12 | 7% |
| Unknown | 43 | 24% |
Attention Score in Context
This research output has an Altmetric Attention Score of 91. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 18 May 2021.
All research outputs
#393,330
of 22,925,760 outputs
Outputs from Gynecologic Oncology Research and Practice
#1
of 34 outputs
Outputs of similar age
#9,095
of 415,362 outputs
Outputs of similar age from Gynecologic Oncology Research and Practice
#1
of 3 outputs
Altmetric has tracked 22,925,760 research outputs across all sources so far. Compared to these this one has done particularly well and is in the 98th percentile: it's in the top 5% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 34 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 10.1. This one scored the same or higher as 33 of them.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 415,362 tracked outputs that were published within six weeks on either side of this one in any source. This one has done particularly well, scoring higher than 97% of its contemporaries.
We're also able to compare this research output to 3 others from the same source and published within six weeks on either side of this one. This one has scored higher than all of them